Eculizumab for atypical hemolytic-uremic syndrome in India: First report from India and the challenges faced

Much progress has been made in understanding the pathophysiology and treatment of atypical hemolytic uremic syndrome (aHUS). Plasma therapy is the mainstay of treatment for aHUS. The availability of the first effective anti-complement therapeutic agent, eculizumab, has dramatically changed the outlo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sethi, S. K., Rohatgi, S., Dragon-Durey, M. A., Raghunathan, V., Dhaliwal, M., Rawat, A., Jha, P., Bansal, S. B., Raina, R., Kher, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5255992/
https://www.ncbi.nlm.nih.gov/pubmed/28182046
http://dx.doi.org/10.4103/0971-4065.179369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5255992/
https://www.ncbi.nlm.nih.gov/pubmed/28182046
http://dx.doi.org/10.4103/0971-4065.179369

Ejemplares similares